Login to Your Account

AstraZeneca Could Pay Up To $340M For Avanir Heart Drug

By Randall Osborne

Tuesday, July 12, 2005
With its Reverse Cholesterol Transport (RCT) program only at the preclinical stage, Avanir Pharmaceuticals Inc. nailed down a potential $340 million development and commercialization deal with AstraZeneca plc, which has agreed to pay $10 million of that amount up front. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription